KRAS and colorectal carcinoma: We observed a synergistic effect of MEKi and PI3Ki on DLD-1 and HCT116 growth (Fig. 6B, C), confirming previous reports of KRAS mutated CRC models, including HCT116 and DLD-1 cells6,51–56.